Suppr超能文献

我们应该做更多的工作,为 COVID-19 的一个重要可改变风险因素——肥胖症——提供基于证据的治疗方法。

We Should Do More to Offer Evidence-Based Treatment for an Important Modifiable Risk Factor for COVID-19: Obesity.

机构信息

University of Minnesota, Minneapolis, MN, USA.

出版信息

J Prim Care Community Health. 2021 Jan-Dec;12:2150132721996283. doi: 10.1177/2150132721996283.

Abstract

Observational studies, from multiple countries, repeatedly demonstrate an association between obesity and severe COVID-19, which is defined as need for hospitalization, intensive care unit admission, invasive mechanical ventilation (IMV) or death. Meta-analysis of studies from China, USA, and France show odds ratio (OR) of 2.31 (95% CI 1.3-4.1) for obesity and severe COVID-19. Other studies show OR of 12.1 (95% CI 3.25-45.1) for mortality and OR of 7.36 (95% CI 1.63-33.14) for need for IMV for patients with body mass index (BMI) ≥ 35 kg/m. Obesity is the only modifiable risk factor that is not routinely treated but treatment can lead to improvement in visceral adiposity, insulin sensitivity, and mortality risk. Increasing the awareness of the association between obesity and COVID-19 risk in the general population and medical community may serve as the impetus to make obesity identification and management a higher priority.

摘要

观察性研究来自多个国家,反复表明肥胖与严重 COVID-19 之间存在关联,严重 COVID-19 定义为需要住院、入住重症监护病房、接受有创机械通气 (IMV) 或死亡。来自中国、美国和法国的研究的荟萃分析显示,肥胖与严重 COVID-19 的比值比 (OR) 为 2.31(95%CI 1.3-4.1)。其他研究显示,肥胖患者的死亡率为 12.1(95%CI 3.25-45.1),需要 IMV 的为 7.36(95%CI 1.63-33.14)。肥胖是唯一未常规治疗的可改变风险因素,但治疗可以改善内脏脂肪、胰岛素敏感性和死亡率风险。提高普通人群和医学界对肥胖与 COVID-19 风险之间关联的认识,可能会促使将肥胖识别和管理作为更高优先级的事项。

相似文献

本文引用的文献

9
Immunomodulation in COVID-19.新型冠状病毒肺炎中的免疫调节
Lancet Respir Med. 2020 Jun;8(6):544-546. doi: 10.1016/S2213-2600(20)30226-5. Epub 2020 May 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验